Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changlin Mei

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
American Journal of Nephrology|February 17, 2021
Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance HemodialysisJianping Jiang, Yuanyuan Zhang, Jianghua Chen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 24, 2013
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration studyNan Chen, Xiongfei Wu, Xiaoqiang Ding, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in ChinaNan Chen, Jiaqi Qian, Jianghua Chen, et al.
BMC Nephrology|September 1, 2012
China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysisFanfan Hou, Jianping Jiang, Jianghua Chen, et al.
Atherosclerosis|August 4, 2012
Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysisJianping Jiang, Pingyan Chen, Jianghua Chen, et al.
Chronic Diseases and Translational Medicine|July 1, 2022
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trialBicheng Liu, Nan Chen, Jinghong Zhao, et al.
Chronic Diseases and Translational Medicine|May 27, 2022
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trailNan Chen, Changying Xing, Jianying Niu, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 5, 2009
Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005Yu Wang, Luxia Zhang, Xiaomei Li, et al.
BMC Nephrology|September 22, 2012
Mineral and bone disorder in Chinese dialysis patients: a multicenter studyXianglei Kong, Luxia Zhang, Ling Zhang, et al.
Kidney International|January 23, 2025
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summaryVicente E Torres, Curie Ahn, Thijs R M Barten, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
American Journal of Nephrology|February 17, 2021
Serum and Tissue Levels of Advanced Glycation End Products and Risk of Mortality in Patients on Maintenance HemodialysisJianping Jiang, Yuanyuan Zhang, Jianghua Chen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 24, 2013
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration studyNan Chen, Xiongfei Wu, Xiaoqiang Ding, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in ChinaNan Chen, Jiaqi Qian, Jianghua Chen, et al.
BMC Nephrology|September 1, 2012
China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysisFanfan Hou, Jianping Jiang, Jianghua Chen, et al.
Atherosclerosis|August 4, 2012
Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysisJianping Jiang, Pingyan Chen, Jianghua Chen, et al.
Chronic Diseases and Translational Medicine|July 1, 2022
Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trialBicheng Liu, Nan Chen, Jinghong Zhao, et al.
Chronic Diseases and Translational Medicine|May 27, 2022
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trailNan Chen, Changying Xing, Jianying Niu, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|June 5, 2009
Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005Yu Wang, Luxia Zhang, Xiaomei Li, et al.
BMC Nephrology|September 22, 2012
Mineral and bone disorder in Chinese dialysis patients: a multicenter studyXianglei Kong, Luxia Zhang, Ling Zhang, et al.
Kidney International|January 23, 2025
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summaryVicente E Torres, Curie Ahn, Thijs R M Barten, et al.
Pageof 19